Saturn V Capital Management LP: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1964437) · Explore on the interactive board
Saturn V Capital Management LP disclosed 23 US equity positions worth $697.5m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is AMLX at 11.9% of the reported book, followed by ALMS, ABVX. The top ten holdings are 75.6% of the book, and the portfolio behaves like about 14 equal-weight positions. Versus the prior filing it opened 3 new positions, added to 12, reduced 6 and exited 1. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Saturn V Capital Management LP own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 3 new, 12 added, 6 reduced, 1 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 11.9% | $83.0m | 4,624,101 | 6% | added |
| 2 | ALMS ALUMIS INC | Healthcare | 11.8% | $82.0m | 2,915,443 | -9% | reduced |
| 3 | ABVX ABIVAX SA | Healthcare | 9.9% | $69.1m | 518,865 | -4% | reduced |
| 4 | PCVX VAXCYTE INC | Healthcare | 7.1% | $49.6m | 852,914 | 3% | added |
| 5 | IMMX IMMIX BIOPHARMA INC | 6.9% | $48.0m | 4,658,429 | 26% | added | |
| 6 | PHVS PHARVARIS N V | Healthcare | 6.5% | $45.4m | 1,314,122 | 9% | added |
| 7 | JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 5.6% | $38.8m | 160,938 | -1% | reduced |
| 8 | CELC CELCUITY INC | Healthcare | 5.6% | $38.7m | 370,318 | 31% | added |
| 9 | IRON DISC MEDICINE INC | Healthcare | 5.5% | $38.4m | 524,730 | 17% | added |
| 10 | CADL CANDEL THERAPEUTICS INC | 4.9% | $34.0m | 3,303,686 | 14% | added | |
| 11 | XFOR X4 PHARMACEUTICALS INC | 4.7% | $32.6m | 6,973,343 | 8% | added | |
| 12 | MNPR MONOPAR THERAPEUTICS INC | 4.1% | $28.9m | 311,976 | -10% | reduced | |
| 13 | DYN DYNE THERAPEUTICS INC | Healthcare | 3.4% | $23.5m | 1,057,493 | 9% | added |
| 14 | TRVI TREVI THERAPEUTICS INC | Healthcare | 2.8% | $19.6m | 1,052,043 | – | new |
| 15 | ZURA ZURA BIO LTD | Healthcare | 1.8% | $12.4m | 2,101,119 | 184% | added |
| 16 | SGMT SAGIMET BIOSCIENCES INC | Healthcare | 1.6% | $11.4m | 1,479,918 | – | new |
| 17 | OCULIS HOLDING AG | 1.4% | $9.5m | 684,880 | 33% | added | |
| 18 | IKT INHIBIKASE THERAPEUTICS INC | 1.1% | $7.9m | 3,869,056 | 0% | held | |
| 19 | VIR VIR BIOTECHNOLOGY INC | Healthcare | 1.1% | $7.9m | 770,643 | – | new |
| 20 | IVVD INVIVYD INC | Healthcare | 1.0% | $7.3m | 8,392,288 | -23% | reduced |
| 21 | ANRO ALTO NEUROSCIENCE INC | Healthcare | 0.7% | $4.8m | 182,829 | 105% | added |
| 22 | MSLE SATELLOS BIOSCIENCE INC | 0.4% | $2.7m | 350,000 | 0% | held | |
| 23 | OVID OVID THERAPEUTICS INC | Healthcare | 0.3% | $1.8m | 663,060 | -84% | reduced |
What did Saturn V Capital Management LP sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| COGT COGENT BIOSCIENCES INC | 100.0% | $24.1m |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 76.5% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Saturn V Capital Management LP's portfolio?
Across every quarter Saturn V Capital Management LP has filed, its median largest position is 12.3% of the book and its median top-ten weight is 76.3%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 1.0 completed holding spells, the median lasted 1.0 quarters; 23.0 positions are still open and their final length is unknown.